PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with resistant leukemia: targeted drug combo enters trial
Disease control Not yet recruitingThis study tests a new drug, asciminib, given with chemotherapy and then with another drug called blinatumomab, in children, teens, and young adults up to age 30 who have a type of leukemia (Ph+ or Ph-like ALL) that has come back or not responded to treatment. The goal is to find…
Matched conditions: PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Real-World data sought on leukemia drug ponatinib
Knowledge-focused Not yet recruitingThis study reviews medical records of about 103 adults with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) who received the drug ponatinib as their first treatment in regular medical practice. Researchers want to see how many patients achieve a deep level of cancer …
Matched conditions: PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Knowledge-focused
Last updated May 11, 2026 20:50 UTC